Needs and Preferences of Patients With Head-neck Cutaneous SCC

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06046625
Collaborator
(none)
15
1
23.9
0.6

Study Details

Study Description

Brief Summary

The care of patients with high-risk cutaneous squamous cell carcinomas in the head-neck area is complex and requires a multidisciplinary approach. A key component in this care is the need and experience of patients. However, studies on the experiences and needs of patients with high-risk cutaneous squamous cell carcinomas in the head-neck region are lacking.

Detailed Description

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer worldwide after basal cell carcinoma. It involves approximately 20% of all cutaneous malignancies and its incidence is still increasing. In 2020, nearly 15,000 cSCCs were reported in the Netherlands, of which approximately 50% concerned patients aged 75 years or older. UV radiation is the main risk factor for development of a cSCC, therefore the majority of cSCCs are localized to the sun-exposed skin in the head-neck region. cSCCs have a metastatic rate of 2.6-5% and recurrence rate of 1.9-3.7%, with rates increasing in high-risk cSCCs. The increasing incidence, advanced age, the (often) high-risk localization in the head-neck area (given functional and cosmetic importance) and the possible high risk of metastasis result in complex care, especially in stage T2 to T4 cSCCs, also known as high-risk cSCCs.

In this complex care, care pathways offer an excellent opportunity to improve multidisciplinary communication, patient satisfaction, quality and efficiency of care. In this, the experiences and needs of patients are of great importance. Previous research on the experiences and needs of patients with skin cancer is limited and particularly focused on melanomas. In 2017, a qualitative systematic review of the experiences and needs of patients with skin cancer found only two studies examining cSCCs. These studies showed that patients perceived clear information, attention to psychosocial aspects and attention to prevention as important.

In 2019, a study of the needs and experiences of patients with keratinocyte carcinomas, conducted through focus groups, showed similar results. Non of these studies examined cSCCs exclusively, nor did they differentiate by location. However, this appears to be relevant, because of the higher impact on the quality of life of patients with skin cancer in visible locations.

Additionally, studies have been conducted into shared-decision making as part of multidisciplinary care. Complex cases are currently often discussed multidisciplinary. However, several studies describe that such a multidisciplinary approach can impede multidisciplinary decision-making because the patient's perspective is often missing. Studies on the experience of patients with cSCCs in the head neck region are lacking.

Study Design

Study Type:
Observational
Anticipated Enrollment :
15 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Needs and Preferences of Patients With High-risk Cutaneous Squamous Cell Carcinomas in the Head Neck Region: a Qualitative Approach
Actual Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Head-neck cutaneous Squamous cell carcinomas

Patients with high risk cutaneous squamous cell carcinoma in the head neck region, receiving regular multidisciplinary care.

Other: Regular care with additional administration of a semi-structured interview
Patients receiving regular care. In addition, a semi-structured interview is conducted. The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement.

Outcome Measures

Primary Outcome Measures

  1. Themes patients [Through study completion, an average of 1 year]

    The emerging themes of patient needs an experiences in the care of cutaneous squamous cell carcinoma in the head-neck region.

  2. Themes professionals [Through study completion, an average of 1 year]

    The emerging themes of professionals' needs in the care of patients with cutaneous squamous cell carcinoma in the head-neck area.

Secondary Outcome Measures

  1. Association themes and patient/tumor characteristics [Through study completion, an average of 1 year]

    The associations between the emerging themes and baseline characteristics (such as gender, age, marital status, education level, world health organisation performance status, informal care, history of skin cancer, co-occurrence of other skin cancers) and tumor characteristics (such as stage of cSCC, differentiation, type of treatment).

  2. Association themes and professional characteristics [Through study completion, an average of 1 year]

    The associations between the emerging themes and characteristics of professionals (gender, age, type of specialty, number of years working as a specialist, number of years of experience within head and neck working group).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with a cSCC, located in the head-neck region

  • who visited the multidisciplinary head-neck team of the Maastricht University Medical Center+

  • who already received treatment for their cSCC

  • who gave informed consent for participation

Exclusion Criteria:
  • patients who are cognitively impaired for participation in an interview

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maastricht University Medical Center+ Maastricht Netherlands

Sponsors and Collaborators

  • Maastricht University Medical Center

Investigators

  • Principal Investigator: K Mosterd, MD, PhD, Maastricht University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT06046625
Other Study ID Numbers:
  • METC 2021-2765
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Maastricht University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023